Metabolic imaging can help advance diagnosis of head and neck cancers through improved visualization of metabolic pathways, hypoxia and tumor-specific receptors, SNM President Dr. Michael M. Graham said during the 2010 ASTRO Multidisciplinary Head and Neck Cancers Symposium. Agents showing promise for molecular imaging of metabolic pathways include FDG, 2-NBDG, FLT, 11C-acetate and amino acids, Graham said. Radiotracers for hypoxia imaging include FMISO and FAZA, and those for tumor-specific receptor imaging include MIBG, ProstaScint and Octrescan. "I think imaging with these agents is going to be huge, particularly as we advance the concept of personalized medicine," Graham said.
Published in Brief: